129 related articles for article (PubMed ID: 28245116)
1. Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
Yu W; Li C; Zhang W; Xia Y; Li S; Lin JY; Yu K; Liu M; Yang L; Luo J; Chen Y; Sun H; Kong L
J Med Chem; 2017 Apr; 60(7):2718-2731. PubMed ID: 28245116
[TBL] [Abstract][Full Text] [Related]
2. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
Zhang W; Guo J; Li S; Ma T; Xu D; Han C; Liu F; Yu W; Kong L
Sci Rep; 2017 Apr; 7():46352. PubMed ID: 28397855
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3).
Chen H; Yang Z; Ding C; Xiong A; Wild C; Wang L; Ye N; Cai G; Flores RM; Ding Y; Shen Q; Zhou J
Eur J Med Chem; 2014 Jul; 82():195-203. PubMed ID: 24904966
[TBL] [Abstract][Full Text] [Related]
4. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells.
Chun J; Li RJ; Cheng MS; Kim YS
Cancer Lett; 2015 Feb; 357(1):393-403. PubMed ID: 25434800
[TBL] [Abstract][Full Text] [Related]
5. Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
Burks HE; Abrams T; Kirby CA; Baird J; Fekete A; Hamann LG; Kim S; Lombardo F; Loo A; Lubicka D; Macchi K; McDonnell DP; Mishina Y; Norris JD; Nunez J; Saran C; Sun Y; Thomsen NM; Wang C; Wang J; Peukert S
J Med Chem; 2017 Apr; 60(7):2790-2818. PubMed ID: 28296398
[TBL] [Abstract][Full Text] [Related]
6. Discovery, synthesis, and evaluation of small-molecule signal transducer and activator of transcription 3 inhibitors.
Shi ZB; Zhao D; Huang YY; Du Y; Cao XR; Gong ZN; Zhao R; Li JX
Chem Pharm Bull (Tokyo); 2012; 60(12):1574-80. PubMed ID: 23207637
[TBL] [Abstract][Full Text] [Related]
7. 10,11-dehydrocurvularin exerts antitumor effect against human breast cancer by suppressing STAT3 activation.
Zhao Q; Bi Y; Zhong J; Li X; Guo J; Liu YX; Pan LR; Tan Y; Deng ZS; Yu XJ
Acta Pharmacol Sin; 2021 May; 42(5):791-800. PubMed ID: 32868906
[TBL] [Abstract][Full Text] [Related]
8. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
[TBL] [Abstract][Full Text] [Related]
9. Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors.
Cai G; Yu W; Song D; Zhang W; Guo J; Zhu J; Ren Y; Kong L
Eur J Med Chem; 2019 Jul; 174():236-251. PubMed ID: 31048139
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.
Nishisaka F; Taniguchi K; Tsugane M; Hirata G; Takagi A; Asakawa N; Kurita A; Takahashi H; Ogo N; Shishido Y; Asai A
Cancer Sci; 2020 May; 111(5):1774-1784. PubMed ID: 32112605
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
[TBL] [Abstract][Full Text] [Related]
12. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein.
Li S; Zhang W; Yang Y; Ma T; Guo J; Wang S; Yu W; Kong L
Eur J Med Chem; 2016 Nov; 124():1006-1018. PubMed ID: 27783972
[TBL] [Abstract][Full Text] [Related]
13. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
14. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
Huang Q; Zhong Y; Li B; Ouyang S; Deng L; Mo J; Shi S; Lv N; Wu R; Liu P; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2021 Oct; 221():113525. PubMed ID: 34000483
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3.
Wang X; He Q; Wu K; Guo T; Du X; Zhang H; Fang L; Zheng N; Zhang Q; Ye F
Eur J Med Chem; 2019 Oct; 179():218-232. PubMed ID: 31254923
[TBL] [Abstract][Full Text] [Related]
16. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
[TBL] [Abstract][Full Text] [Related]
17. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
[TBL] [Abstract][Full Text] [Related]
18. Cosmomycin C inhibits signal transducer and activator of transcription 3 (STAT3) pathways in MDA-MB-468 breast cancer cell.
Kim J; Lee YJ; Shin DS; Jeon SH; Son KH; Han DC; Jung SN; Oh TK; Kwon BM
Bioorg Med Chem; 2011 Dec; 19(24):7582-9. PubMed ID: 22071520
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis and Anti-breast Cancer Activity of Some Novel Substituted Isoxazoles as Anti-breast Cancer Agent.
Mokale SN; Sakle NS; Bhavale SA; Lokwani DK; Shelke VR
Anticancer Agents Med Chem; 2018; 18(7):1009-1015. PubMed ID: 29189180
[TBL] [Abstract][Full Text] [Related]
20. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
